Adora Life Sciences

Patented Topical Treatment Slows The Progression Of Osteoarthritis

About this Event

Adora Life Science recently announced that its new U.S. patent number 12,303,528 was issued May 20, 2025. This potential revolutionary patent covers claims for topical formulations of PSGAG containing skin penetrating enhancers for treatment of joint pain and stiffness. These patents do not expire until late September 2043, at the earliest. Additional claims are being pursued in the U.S. and globally.

Adora’s lead candidate, based on topical PSGAG, is designed to deliver anti-inflammatory and cartilage-protective effects directly to the affected joint or tissue — without the risks associated with injectable or oral drugs. Unlike conventional pain relievers, the compound has shown in scientific literature the potential to preserve cartilage, reduce joint degradation, and improve long-term outcomes.

Register today to watch our Fireside Chat with the Adora team to hear more about this strong and exciting new treatment in an $8+ billion market.

Video On Demand

– Recorded

June 11

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.